Pharnext esPharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

Biotechnology

Pharnext

Pharnext's headquarters in Issy-les-Moulineaux, France

Hugo Brugière

Vincent Serra

Gilbert Wagener

Serguei Nabirotchkine, PhD

Lawrence Steinman

James Kuo

The Leadership Team at Pharnext oversees the strategic direction and operational execution of the company’s innovative biopharmaceutical initiatives. Comprising experts in medicine, science, manufacturing, and quality, the team is responsible for guiding the advancement of Pharnext's clinical programs, including PXT3003 and PXT864, while fostering the development of the PLEOTHERAPY™ drug discovery paradigm. Their collaborative efforts ensure the robust progression of research, regulatory compliance, and the optimization of product development to meet the needs of patients with complex diseases.

Leadership Team

The Clinical Operations and Development team at Pharnext is responsible for designing, implementing, and managing clinical trials for the company's lead products, including PXT3003 and PXT864. This team works to ensure the trials are conducted in compliance with regulatory standards, oversees data collection and analysis, and collaborates with international investigators to facilitate successful trial completion. Their goal is to advance the clinical development pipeline efficiently and safely, contributing to the overall mission of developing innovative treatments for neurological diseases.

Pharnext

Org chart

Board & advisors

Teams

Leadership Team

Clinical Operations and Development

Offices

Pharnext

Org chart

Board & advisors

Teams

Leadership Team

Clinical Operations and Development

Offices

Related companies